Trial intelligence / Profile preview

Atezolizumab plus capecitabine vs capecitabine as adjuvant therapy in triple receptor-negative breast cancer with residual invasive disease after neoadjuvant chemotherapy

KCT0003426Phase 2Not yet recruiting

Sponsor

Roche

Start

Jan 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1